Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I), wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

Abstract: An object of the present invention is to provide a method for detecting particulate substances with a high degree of sensitivity, while suppressing the generation of non-specific signals. According to the present invention, the generation of non-specific signals in the background can be suppressed by blocking a membrane of a test strip which is used for immunochromatography with a blocking composition including a polymer-based blocking agent having, in its side chain, a substituent represented by the following formula: (wherein R1, R2, and R3 are each independently a hydrogen atom, a C1-6 alkyl group, or a C1-6 hydroxyalkyl group; and n is an integer of 1 to 4), and having a weight average molecular weight (Mw) of 1×103 to 1×107.

Abstract: Provided is a method of assisting breast cancer diagnosis, comprising: a measuring step for measuring an amount of laminin 5 or laminin ?3 in a specimen; and an information-providing step for providing information for breast cancer diagnosis based on the amount of laminin 5 or laminin ?3 thus measured. Provided is a test kit for breast cancer comprising an anti-laminin 5 antibody or an anti-laminin ?3 antibody.

Abstract: The present invention relates to a method for detecting a particulate substance by immunochromatography, the particulate substance including, on its surface, a plurality of substances to be bound containing a first substance to be bound and a second substance to be bound which may be the same or different with respect to each other, wherein the method includes the steps of: (1) contacting on a membrane a sample containing the particulate substance with a first specific binding substance for the first substance to be bound to capture the particulate substance with the first specific binding substance; (2) contacting the captured particulate substance with a second specific binding substance for the second substance to be bound to label the particulate substance; and (3) detecting the labeled particulate substance, wherein the first specific binding substance is immobilized on the membrane, and the second specific binding substance is bound to a metal nanoparticle.

Abstract: A method for evaluating a sample includes obtaining a blood plasma sample prepared from human blood, conducting detection of a predetermined molecule in the blood plasma sample, and evaluating the quality of the blood plasma sample based on the intensity of the molecule acquired by the detection.

Abstract: The present invention provides a method for quantifying a plurality of surface antigens simultaneously, thereby identifying an extracellular vesicle such as an exosome, and detecting and quantifying any surface antigen. Specifically, the present invention provides a method for detecting an extracellular vesicle, the method including: a step of labeling an extracellular vesicle in a sample using a first metal labeling reagent for labeling a nucleic acid and a second metal labeling reagent for labeling an extracellular vesicle surface antigen; and a step of identifying the first and second metal labeling reagents by mass spectrometry.

Abstract: The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method.

Abstract: Disclosed is a method of analyzing an oxidation state of a methionine residue in a protein sample, which comprises the steps of: inducing a reaction between a protein sample having a methionine residue with an oxidation state to be analyzed, and hydrogen peroxide H218O2 having oxygen atoms labeled by the isotope 18O, to obtain a modified protein sample in which the oxidation state of the methionine residue is stabilized; and subjecting the modified protein sample to a measurement to quantify an oxidation degree of the methionine residue. Preferably, the measurement is a mass spectrometric (MS) measurement using a mass spectrometer. The method can analyze an oxidation state of a methionine residue in a protein sample, in a simple manner, while accurately reflecting an in vivo oxidation state of the methionine residue.

Abstract: The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method.